Contact Us
Drug Search Results
More Filters [+]

GSK-1795091

Alternative Names: gsk-1795091, gsk1795091, gsk 1795091
Latest Update: 2022-11-01
Latest Update Note: PubMed Publication

Product Description

 a synthetic TLR4 agonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32739049/)

Mechanisms of Action: TLR4 Agonist

Novel Mechanism: Yes

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-1795091

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified|Oncology Unspecified|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT03447314

P1

Completed

Oncology Solid Tumor Unspecified

2020-07-01

NCT02798978

P1

Completed

Oncology Unspecified|Healthy Volunteers

2017-10-13

Recent News Events

Date

Type

Title

11/01/2022

PubMed

 Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.

08/01/2020

PubMed

 Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions